Drugs / EVATANEPAG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00533377 | Jan 2008 → May 2010 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVATANEPAG | ChEMBL registry synonym — accepted as the source's own label CHEMBL563646 ↗ |
| Known as | C-533,536-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL563646 ↗ |
| Known as | CP-533, 536 | “investigational drug called CP-533,536” NCT00533377 ↗1“Drug: CP-533, 536” NCT00533377 ↗ |
| Known as | CP-533,536-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL563646 ↗ |
| Known as | EVATANEPAG SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL563646 ↗ |
| Action | Activate | “Prostanoid EP2 receptor agonist” CHEMBL563646 ↗ |
| Modality | Small molecule | — CHEMBL563646 ↗ |
| Target | PTGER2 | “Prostanoid EP2 receptor agonist” CHEMBL563646 ↗ |